A groundbreaking advancement in therapeutic methods has been reported by researchers at Harvard Medical School and Brigham and Women's Hospital, who have engineered an oral capsule designed to deliver liquid mRNA for gut-targeted therapy. This innovation represents a significant departure from traditional injection methods, providing a potential solution for various chronic conditions requiring repeated doses.

The Challenges of mRNA Delivery

Current mRNA-based medications, including vaccines, typically require injection, which poses several challenges:

  • Limited Home Use: Injections necessitate professional administration, restricting patient autonomy, especially in chronic conditions.
  • Distribution Issues: During outbreaks, the logistics of injecting large populations can be slow and cumbersome.
  • Patient Preference: Many patients strongly prefer the convenience of oral medications over injections.

These challenges highlight the vital need for alternative methods to effectively target gastrointestinal tissues, where oral administration would be especially advantageous.

Overcoming Biological Barriers

Oral delivery of mRNA therapeutics faces several biological barriers, specifically:

  • Stomach Acid: The acidic environment can degrade mRNA before it reaches the intestines.
  • Intestinal Mucus: Mucus can interfere with the mRNA's ability to penetrate cell membranes.

Although nanoparticles have emerged as a protective measure, their efficacy diminishes rapidly before reaching the upper gastrointestinal tract.

The RNACap Solution

The researchers introduced an engineered capsule known as RNACap, described in their study, Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease, published in Science Translational Medicine. Key features of RNACap include:

Feature Function
pH-Sensitive Coating Protects mRNA in the acidic stomach environment.
Pressure-Triggered Release Membranes Ensures the capsule remains intact until reaching the intestines.
Nanoparticle Formulation Utilizes G0-C14, PLGA, and PEG-lipid for effective mucus penetration and endosomal escape.

Results of the Study

The results from preclinical studies demonstrated the potential of RNACap:

  • In rats, the administration of interleukin-10 (IL-10) mRNA via RNACap resulted in significantly increased levels of IL-10 protein in both serum and colon tissue.
  • Notably, RNACap reduced the levels of proinflammatory cytokines, showcasing its therapeutic efficacy in acute and delayed dextran sodium sulfate-induced colitis models.
  • No toxicity was detected in any of the assessments performed, including blood chemistry and histological examinations.

In the swine model, measurable mRNA expression was observed within just 8.5 hours post-administration, further emphasizing the capsule's efficacy.

Implications for Future Therapeutics

The authors conclude that RNACap shows promise as a platform for the oral delivery of mRNA therapeutics, particularly in treating intestinal diseases and potentially other medical conditions. Its compatibility with liquid formulations eliminates the need for lyophilization, a costly process that can compromise mRNA efficacy and complicate distribution logistics.

Next Steps

Further research is necessary to optimize the RNACap for human applications and validate its effectiveness in clinical settings. The comprehensive features of RNACap convey a substantial step forward in the administration of mRNA therapeutics.

Literature Cited

[1] Huang, X., et al. (2025). Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease. Science Translational Medicine.

For an extensive review of the study and its implications, please refer to the original article available at Phys.org.